Marketing authorisation application

Colin Kerr

Posted: Saturday, February 1, 2020

Aerie Pharmaceuticals has submitted the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the European Medicines Agency (EMA). Roclanda® is currently marketed in the US as Rocklatan®.
”As EMA review of the Roclanda® MAA begins, we will be completing and analysing our Mercury 3 study, which compares Roclanda®to the leading fixed-dose combination product in the EU,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie.

Latest Articles

escrs members advert